Join our Fourth session on the D-Dimer in Cancer and VTE with Prof. Anna Falanga!
About this webinar
Thrombosis in Cancer patient is an association that has been identified for quite some time even if all the mechanisms that induce thrombosis in cancer are still of in the process of being fully understood. What is known is that the type of Cancer, its stage, any tumor-derived factors or genetics can all affect the thrombotic risk in cancer.
Cancer impacts all components of Virchow’s triad Stasis through vascular compression and bed rest, Endothelial Damage by tumor vascular damage, and Hypercoagulability through the expression of procoagulant factors. In addition, cancer has some specific inflammatory actions that adds to the hypercoagulable state which makes Venous Thromboembolism the second cause of mortality in cancer patients.
To better evaluate the risk of thrombosis in Cancer patients, risk assessment tools were created and validated to calculate the risk of thrombosis in cancer patients. For example, the Khorana score is the most validated risk assessment tool in cancer patients and is validated primarily for outpatients and general cancer patients (i.e., solid tumors and lymphomas; not to be used for patients with brain tumors or myelomas) to predict thrombosis. Another example is the Vienna score which is a similar score but also includes measures of D-Dimer and soluble P-selectin (sP-selectin). Please join us for the talk by Professor Anna Falanga who provides a comprehensive overview of Cancer-Associated Thrombosis.
Schedule your webinar below!